This news release is not for distribution or dissemination in the United States of America

TORONTO, ON / ACCESSWIRE / June 26, 2020 / GreenBank Capital Inc (CSE:GBC)(OTCMKTS:GRNBF) ("GreenBank or the Company") announces that pursuant to the blanket relief granted by the Canadian Securities Administrators it will not file its interim financial statements for the 9 months ended April 30, 2020 and the related management's discussion and analysis and officer certifications, as required by Part 4 and Part 5 of National Instrument 51-102: Continuous Disclosure Obligations (collectively, the "Interim Filings") by the filing deadline of June 29, 2020.

The Company will rely on an exemption set out in Ontario Instrument 51-505: Temporary Exemption from Certain Corporate Finance Requirements which provides blanket relief of a 45-day extension provided for periodic filings normally required to be made by issuers during the period from June 2, 2020 to August 31, 2020. The Company expects to file the Interim Filings by July 29, 2020.

The Company confirms that its management and other insiders are subject to an insider trading black-out policy that reflects the principles in section 9 of National Policy 11-207: Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions. Directors and officers are subject to a black-out period for a period of two trading days after the Interim Filings have been filed and disclosed by way of a news release.

Other than the business developments that have been previously disclosed and filed on SEDAR, the Company confirms that there have been no material business developments since the filing of its interim financial statements on April 1, 2020.

About GreenBank

GreenBank is a merchant banking business listed on the Canadian Securities Exchange (trading symbols CSE: GBC and OTCMKTS: GRNBF and FRA: 2TL). GreenBank's 100% subsidiary GreenBank Financial Inc. is a merchant bank. GreenBank's portfolio companies comprise equity investments in 11 small cap businesses, namely; 52.5% of Blockchain Evolution Inc, owners of the world's first identification based blockchain, and developers of Xbook a user permissioned and revenue sharing social media platform; 22.6% of Ubique Minerals Limited, a zinc exploration company in Newfoundland, Canada; 47.7% of GBC Grand Exploration Inc, a gold exploration company in Newfoundland, Canada;; 59.5% of Kabaddi Games Inc, developers of a mobile application game based on the sport of Kabaddi;; 19% of Inside Bay Street Corporation, a financial news communications company; 34.8% of Gander Exploration Inc, a minerals exploration company in Newfoundland, Canada; 10% of Reliable Stock Transfer Inc, a Canadian small cap transfer agency; 25% of Buchans Wileys Exploration Inc, a minerals exploration company with interests in Newfoundland, Canada; 19% of Staminier Limited, a United Kingdom Merchant Banking firm, 10% of The Lonsdale Group LLC, a USA based private equity company focused on small cap investments;; and 11.2% of Minfocus Exploration Corp (TSXV: MFX), a mineral exploration company.

For more information please see https://www.GreenBankCapitalinc.com or contact Mark Wettreich at (647) 693 9411 or by email Mark@GreenBankCapitalinc.com

Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business and trading in the common stock of GreenBank Capital Inc., the raising of additional capital and the future development of the businesses comprising GreenBank's investment portfolio. The forward-looking information is based on certain key expectations and assumptions made by the company's management. Although the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GreenBank can give no assurance that they will prove to be correct. These forward-looking statements are made as of the date of this press release and GreenBank disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release

SOURCE: GreenBank Capital Inc.

ReleaseID: 595384

WINNIPEG, MB / ACCESSWIRE / June 26, 2020 / FP Newspapers Inc. (TSXV:FP)(OTC PINK:FPNUF) ("FPI") announces that all resolutions presented at the Corporation's annual meeting held on June 26, 2020 were approved by the shareholders. The proxy results on the election of directors were as follows:

Name of Nominee

Votes For

Votes Withheld

Phil de Montmollin

2,061,984 (99.77%)

4,700 (0.23%)

Stephen Dembroski

2,057,658 (99.56%)

9,026 (0.44%)

Darryl Levy

2,062,084 (99.78%)

4,600 (0.22%)

Aldo Santin

2,050,963 (99.24%)

15,721 (0.76%)

Phil de Montmollin (as the Corporation's nominee as a director of FPCN General Partner Inc.)

2,061,984 (99.77%)

4,700 (0.23%)

Stephen Dembroski (as the Corporation's nominee as a director of FPCN General Partner Inc.)

2,061,984 (99.77%)

4,700 (0.23%)

Darryl Levy (as the Corporation's nominee as a director of FPCN General Partner Inc.)

2,062,084 (99.78%)

4,600 (0.22%)

Robert Silver, who serves as Chairman of the Corporation, was also re-elected as director of the Corporation by FPCN Media Management Inc. pursuant to its rights as the holder of preferred shares.

About FPI

FPI owns securities entitling it to 49% of the distributable cash of FP Canadian Newspapers Limited Partnership ("FPLP"). FPLP owns the Winnipeg Free Press, the Brandon Sun, and their related businesses, as well as the Canstar Community News division, the publisher of six community newspapers in the Winnipeg region, The Carillon in Steinbach with its related commercial printing operations. The businesses employ approximately 364 full-time equivalent people in Winnipeg, Brandon, Steinbach, Manitoba.

Further information can be found at www. www.fpnewspapers.com and in disclosure documents filed by FP Newspapers Inc. with the securities regulatory authorities, available at www.sedar.com.

For further information please contact:

Daniel Koshowski, CFO
FP Newspapers Inc.
Phone (204) 771-1897

SOURCE: FP Newspapers Inc.

ReleaseID: 595382

REDWOOD CITY, CA / ACCESSWIRE / June 26, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 20,000,000 shares of its common stock at a price of $0.27 per share, for total gross proceeds of approximately $5.4 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 15% additional shares of common stock to cover over-allotments, if any. The shares were offered pursuant to a registration statement on Form S-1 (File No. 333-239177) previously filed with the Securities and Exchange Commission (SEC), and a related registration statement on Form S-1 (File No. 333-239398) filed pursuant to rule 462(b) of the Securities Act of 1933, which registration statements were declared effective by the SEC. A final prospectus relating to the offering was filed with the SEC and is available on the SEC's website at www.sec.gov.

Aegis Capital Corp. is acting as sole bookrunner for the offering.

A copy of the final prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th floor, New York, NY 10019, by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Investor Contact:

Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200

Safe Harbor Disclosure

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the option granted by the Company to the underwriters and other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: the effects of the COVID-19 pandemic on our operations and general economic conditions; risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the SEC on March 6, 2020 and in our other filings with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

SOURCE: Avinger, Inc.

ReleaseID: 595381

NEW YORK, NY / ACCESSWIRE / June 26, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Ryder System, Inc. (NYSE:R)

CONTACT JAKUBOWITZ ABOUT R:
https://claimyourloss.com/securities/ryder-system-inc-loss-submission-form/?id=7592&from=1

Class Period : July 23, 2015 – February 13, 2020

Lead Plaintiff Deadline : July 20, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Ryder's financial results were inflated as a result of the Company's practice of overstating the residual values of the vehicles in its fleet; (2) there was no reasonable basis to believe that Ryder would sell its used vehicles for the amounts that it had assigned to them; (3) Ryder's residual values for its fleet of vehicles exceeded the expected future values that would be realized upon the sale of those vehicles; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Endo International Plc (NASDAQ:ENDP)

CONTACT JAKUBOWITZ ABOUT ENDP:
https://claimyourloss.com/securities/endo-international-plc-loss-submission-form/?id=7592&from=1

Class Period : August 8, 2017 – June 10, 2020

Lead Plaintiff Deadline : August 18, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Endo's and/or its subsidiaries' contributions to the opioid crisis (including, but not limited to, their opioid products' disproportionately negative impact on New York and the fraud that Defendants perpetrated on the New York insurance market) were larger in scope than the Company had represented; (ii) part of that contribution to the crisis included Endo publishing and disseminating false information to health care providers regarding the risks and benefits of opioids; (iii) the foregoing, once revealed, was foreseeably likely to subject Endo and/or its subsidiaries to increased regulatory scrutiny and enforcement, as well as significant financial and/or reputational harm, particularly with respect to New York; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Chembio Diagnostics, Inc. (NASDAQ:CEMI)

CONTACT JAKUBOWITZ ABOUT CEMI:
https://claimyourloss.com/securities/chembio-diagnostics-inc-loss-submission-form/?id=7592&from=1

Class Period : March 12, 2020 – June 16, 2020

Lead Plaintiff Deadline : August 17, 2020

According to the filed complaint, defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Chembio's stock price and operated as a fraud or deceit by misrepresenting the efficacy of the Company's Dual Path Platform ("DPP") COVID-19 test. Defendants allegedly achieved this by making false statements about Chembio's DPP COVID-19 test, although they knew or at least recklessly disregarded that there were material performance concerns with the test. When defendants' prior misrepresentations were disclosed and became apparent to the market, the price of Chembio stock fell precipitously as the prior artificial inflation came out of Chembio's stock price.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

ReleaseID: 595379

SUGAR LAND, TX / ACCESSWIRE / June 26, 2020 / Neutra's wholly owned subsidiary VIVIS Corporation starts its first large marketing campaign by sponsoring and competing in the D3eSports Cup Championship. This D3eSports Cup will be held on the globally recognized Forza Motorsports 7 platform. Esports have continued its global growth audience to over 443 Million, according to Green Man Gaming. (Forbes Article, 12/09/19) VIVIS Corporation will be joining other globally recognized powerful companies that will be promoting their brand in this platform. Gaming is the fastest-growing form of entertainment in the world. (Yahoo Finance, 09/11/2020)

"eSports continues to grow with our youth and what better way to educate our youth with a platform as great as this one," said Neutra CEO Sydney Jim. "We are all about education in our products and our industry, so what a better way to spread the word."

The D3eSports Championship will be broadcasted over D3eSports Channel on Twitch TV.

The schedule for the races are as follows:

June 28th, 2020 – 2:00 PM EDT – Road America (Wisconsin, USA)

July 5th, 2020 – 2:00 PM EDT – Brands Hatch (England)

July 12th, 2020 – 2:00 PM EDT – Watkins Glen (New York, USA)

July 19th, 2020 – 2:00 PM EDT – Sebring International Raceway (Florida, USA)

July 26th, 2020 – 2:00 PM EDT – Michelin Raceway Road Atlanta (Georgia, USA)

The events will be archived on D3eSports YouTube Channel 24 hours after the event.

Neutra's biggest milestone thus far has been the opening of its new production facility in Houston. The site will initially be able to extract over 30,000 lbs per month of hemp biomass, remediate over 200 liters per month of distillate and manufacture a suite of end-user products such as tinctures, topical, etc. The facility will also service companies looking to white label or private label their own branded products, as well as farms that need rolling services.

The site has only been open for a short time, but it has already produced its first batch of VIVIS-branded CBD products. These have been sent to a third-party for purification and potency testing. VIVIS, Neutra's wholly owned subsidiary, requires third-party testing and certification for all its products, a key differentiator between it and competing brands. Thanks to this rigorous testing process, consumers can rest assured they are getting top-quality for their money.

About Neutra Corp.

Neutra Corp. (OTC PINK:NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture-one where in which consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving hemp-based CBD market, in which the Company intends to participate. For more information, visit the Company's website at https://neutrainc.com

NOTICE REGARDING FORWARD LOOKING STATEMENT

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

Neutra Contact:

Sydney Jim
888-433-4033
info@neutrainc.com

SOURCE: Neutra Corp

ReleaseID: 595366

NEW YORK, NY / ACCESSWIRE / June 26, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Casper Sleep Inc. ("Casper" or the Company") (NYSE:CSPR) pursuant and/or traceable to the Company's initial public offering conducted on or about February 7, 2020 (the "IPO" or "Offering"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/cspr.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

The complaint alleges that the Offering Materials issued connected to the Company's IPO were materially false and/or misleading and/or omitted or misrepresented the following facts: (1) Casper's profit margins were actually declining, rather than growing; (2) Casper was changing an important distribution partner, costing it 130 basis points of gross margin in the first quarter of 2020 alone; (3) Casper was holding a glut of old and outdated mattress inventory that it was selling at steeply discounted clearance prices, further impairing the Company's profitability; (4) Casper was suffering accelerating losses, further placing its ability to achieve positive cash flows and profitability out of reach; (5) Casper's core operations were not profitable, but were causing the Company to suffer over $40 million in negative cash flows during the first quarter of 2020 alone and doubling its quarterly net loss year over year; (6) as a result of the foregoing, Casper's ability to achieve profitability, implement its growth initiatives, and expand internationally had been misrepresented in the Offering Documents, as the Company needed to shutter its European operations, halt all international expansion, jettison over one fifth of its global corporate workforce, and significantly curtail new store openings in order to avoid an imminent cash and liquidity crisis, let alone achieve positive operating cash flows; and (7) as a result of the foregoing, Casper's revenue growth rate was not sustainable and had not positioned the Company to achieve profitability.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/cspr or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Casper you have until August 18, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 594674

LOS ANGELES, CA / ACCESSWIRE / June 26, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against PlayAGS, Inc. ("PlayAGS" or "the Company") (NYSE:AGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between August 2, 2018 and August 7, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before August 24, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. PlayAGS was experiencing severe challenges in its Oklahoma business. These challenges were likely to negatively impact the Company's recurring revenue. The Company was also experiencing trouble with its interactive business segment, such as delays in securing regulatory approvals. These challenges were likely to result in the Company recording a goodwill impairment. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about PlayAGS, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 595374

Proven safe sanitizing technology to be on display for virtual "party with a purpose" streaming live at 8 p.m. EST

ORLANDO, FL / ACCESSWIRE / June 26, 2020 / When Hall of Fame legend and four-time NBA champion Shaquille O'Neal and three-time Super Bowl champion Rob Gronkowski go head-to-head for a series of live-streamed entertaining challenges Saturday night, they will have peace of mind that their production sets have been disinfected and protected with the BIOPROTECTUs System products along with sanitizer for everyone's hands. BioSupplies.com is the preferred partner of ViaClean Technologies, which manufactures the BIOPROTECT Hydrating Hand Sanitizer.

Shaq's Fun House vs Gronk Beach is being billed as a virtual party with a purpose. Shaq and Gronk will compete in six "epic" live challenges such as sports trivia, a game of horse, a lip sync battle, a cook-off, a chicken wing eating contest and jousting. The sports trivia segment will be presented by BioSupplies.com. The winner of each competition will earn a donation from the presenting sponsor of the segment to the charity of his choice-the NAACP for Gronkowski and The Boys & Girls Clubs of America for O'Neal.

Both superstar competitors will use the BIOPROTECT Hydrating Hand Sanitizer prior to each new challenge. When applied following label directions, the product protects against germs for up to six hours. This unique hand sanitizer is also infused with aloe and glycerin to moisturize hands.

"While this virtual party will be for fun and for a good cause, fact is, staying protected from problematic viruses and germs is now more serious business than ever before," said A.J. Manaseer, Vice President of BioSupplies.com. "We have the technology that is revolutionizing how that should be done safely and effectively, and the long-lasting hand sanitizer will further help prevent the spread of those germs."

In addition to the challenges, there will be special music performances by Carnage, DaBaby, Diplo, Steve Aoki and Snoop Dogg.

The free, one-of-a-kind global live stream of Shaq's Fun House vs Gronk Beach will start at 8 p.m. EST on Saturday, June 27. For more information visit www.shaqvsgronk.com.

###

About BioSupplies.com

BioSupplies.com is a leading vendor of products and solutions geared towards keeping people and facilities safe from constantly changing health threats endangering our world. BioSupplies.com is proud to offer the BIOPROTECTUs™ System with the hopes of helping our nation regain the peace of mind that our homes, offices, schools, hospitals, or any public facility are kept safe and clean. BioSupplies.com is a ViaClean Authorized Distributor.

About BIOPROTECT™:

The BIOPROTECTUs™ System by ViaClean Technologies, encompasses an array of EPA registered and FDA compliant technologies that disinfect surfaces and spaces as well as provide long-term antimicrobial protection. An essential component in the BIOPROTECTUs™ System is BIOPROTECT™ (https://bioprotect.us/); a groundbreaking, water-based antimicrobial product that when applied to both porous and non-porous surfaces, creates a highly durable protective shield that provides long-term antimicrobial protection that inhibits and prevents the growth and spread of problematic bacteria, fungi, algae, mold and viruses. Extensive laboratory testing has established and corroborated that the BIOPROTECTUs™ System quickly eliminates and provides long-term eradication and suppression of germs and microorganisms. Additional testing has begun, under the auspices of the world-renowned Global Virus Network (www.gvn.org), at two of the organization's Centers of Excellence, to confirm the efficacy of BIOPROTECT™ on SARS-CoV-2.

About Shaq's Fun House vs. Gronk Beach Live Streamed Event:

The one-of-a-kind global livestream will be produced in partnership by: Medium Rare and ABG Entertainment. Fans can tune in from around the world to watch Shaq's Fun House vs. Gronk Beach Presented by The General Insurance free of charge at: www.ShaqVsGronk.com and directly on TikTok. SHAQ & GRONK have also partnered with LiveXLive to simulcast the live stream across 20+ other platforms including: LiveXLive, Facebook, Twitch, Youtube, Twitter.

Media Contact For BioSupplies.com

Daniel Benjamin, BoardroomPR
Email: dbenjamin@boardroompr.com
Phone: 954-370-8999 or 954-618-8287

SOURCE: BioSupplies.com

ReleaseID: 595367

LOS ANGELES, CA / ACCESSWIRE / June 26, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against ProAssurance Corporation ("ProAssurance" or "the Company") (NYSE:PRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between April 26, 2019 and May 7, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before August 17, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. ProAssurance failed to maintain appropriate controls on underwriting and risk management, particularly in setting lose reserves. The Company was incapable of properly assessing a major healthcare account whose losses far exceeded assumptions that were made in underwriting. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about ProAssurance, investors suffered damages.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 595371

LOS ANGELES, CA / ACCESSWIRE / June 26, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Endo International plc ("Endo" or "the Company") (NASDAQ:ENDP) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Endo is the subject of a press release from the New York Department of Financial Services ("DFS") published on June 10, 2020. According to the DFS, it "has filed charges and initiated administrative proceedings against Endo International plc and its subsidiaries, Endo Health Solutions Inc., Endo Pharmaceuticals, Inc., and Par Pharmaceutical Companies, Inc." The charged on based on an ongoing DFS investigation of companies that created and perpetuated the opioid crisis." According to the release, "The DFS' statement of charges alleges that like other opioid Manufactures, Endo . . . knowingly furthered a false narrative to legitimize opioids as appropriate for broad treatment of pain by downplaying their long-known addictive nature and risks"; "misrepresented the safety and efficacy of opioids, without legitimate scientific substantiation"; and "deployed a large sales force to target healthcare providers directly with these misrepresentations." Based on this news, shares of Endo fell sharply, harming investors.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 595370